EOLS

Evolus Inc

EOLS.US evolus.com + Research + Basket
CIK 0001570562
Employees 353
Phone 949 284 4555
Fiscal year end December
IPO Feb 08, 2018
Address 520 Newport Center Drive, Newport Beach, CA, United States, 92660
7.52
-0.12 (-1.51%)
USD · NASDAQ
52-week range
3.86
9.31
Trading at 67% of the 52-week range
Market Cap
504.30M
P/E Ratio
0.00
Forward P/E
15.67
Book Value
-0.47
Div. Yield
N/A
% Institutions
77.67%
% Insiders
11.25%

1 Year

+9.6%

3 Year

-1.2%

10 Year

-34.6%
Description

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Actions

Add an action for EOLS.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. David Moatazedi President, CEO & Director 1978
Ms. Tatjana Mitchell Chief Financial Officer NA
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of Research & Development 1962
Mr. Nareg Sagherian Head of Global Investor Relations & Corporate Communications NA
Mr. Kurt Knab Senior Vice President of Sales NA
Ms. Jessica Novak Senior Vice President of Human Resources NA
Mr. Jeffrey J. Plumer Corporate Secretary NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 20, 2026 David Moatazedi N/A Sale 13.67K $4.75 $64.93K SEC
Mar 20, 2026 Rui Avelar N/A Sale 3.12K $4.75 $14.82K SEC
Mar 17, 2026 David Moatazedi N/A Sale 116.72K $4.89 $570.76K SEC
Mar 17, 2026 Rui Avelar N/A Sale 30.00K $4.89 $146.68K SEC
Dec 22, 2025 David Moatazedi N/A Sale 10.54K $7.15 $75.35K SEC
Dec 22, 2025 Rui Avelar N/A Sale 2.26K $7.15 $16.17K SEC
Aug 22, 2025 Tomoko Yamagishi-Dressler N/A Sale 5.72K $7.51 $42.97K SEC
Aug 15, 2025 Brady Stewart N/A Purchase 30.00K $6.82 $204.60K SEC
Jun 16, 2025 David Moatazedi N/A Sale 16.58K $9.89 $164.00K SEC
Jun 13, 2025 David Moatazedi N/A Sale 111.32K $10.05 $1.12M SEC
Jun 09, 2025 Albert G White III N/A Purchase 20.00K $9.45 $189.00K SEC
May 13, 2025 Sandra Beaver N/A Sale 6.49K $10.02 $65.07K SEC
May 12, 2025 David Moatazedi N/A Sale 15.79K $9.87 $155.82K SEC
May 12, 2025 Rui Avelar N/A Sale 3.39K $9.87 $33.41K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Nantahala Capital Management, LLC 11.20M Jun 30, 2026 16.96% $1.29 75.70%
BlackRock Inc 4.84M Jun 30, 2026 7.33% $0.00 12.83%
BRAIDWELL LP 3.16M Jun 30, 2026 4.78% $0.81 1.61%
Frazier Life Sciences Management, L.P. 2.63M Jun 30, 2026 3.98% $0.40 0.00%
Perceptive Advisors LLC 2.46M Jun 30, 2026 3.72% $0.26 91.11%
Vanguard Capital Management, LLC 2.36M Jun 30, 2026 3.58% $0.00 -4.35%
Assenagon Asset Management SA 1.82M Jun 30, 2026 2.75% $0.01 203.67%
Millennium Management LLC 1.79M Jun 30, 2026 2.71% $0.00 22.36%
State Street Corp 1.70M Jun 30, 2026 2.57% $0.00 28.51%
Geode Capital Management, LLC 1.61M Jun 30, 2026 2.44% $0.00 16.44%
Stonepine Capital Management Llc 1.59M Jun 30, 2026 2.41% $6.23 -9.60%
Point72 Asset Management, L.P. 1.51M Jun 30, 2026 2.28% $0.01 0.00%
Pinnacle Associates Inc 1.49M Jun 30, 2026 2.25% $0.11 28.33%
Armistice Capital, LLC 1.44M Jun 30, 2026 2.17% $0.12 2.87%
Rice Hall James & Associates, LLC 1.29M Jun 30, 2026 1.95% $0.44 2.79%
AWH Capital, L.P. 1.25M Jun 30, 2026 1.89% $3.01 100.00%
The Goldman Sachs Group Inc 1.22M Jun 30, 2026 1.85% $0.00 12.24%
Soleus Capital Management, L.P. 822.43K Jun 30, 2026 1.25% $0.20 -63.37%
Soviero Asset Management, LP 770.00K Jun 30, 2026 1.17% $2.25 13.17%
UBS Group AG 752.68K Jun 30, 2026 1.14% $0.00 -0.03%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Russell 2000 ETF 1.55M 2.34% ▼ 1.14% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.54M 2.34% ▲ 0.00% Sep 30, 2026
3 Fidelity Small Cap Index 645.69K 0.98% ▲ 0.50% Jul 31, 2026
4 iShares Russell 2000 Growth ETF 544.86K 0.82% ▼ 0.13% Sep 30, 2026
5 State Street® SPDR® S&P® PhrmctlsETF 471.62K 0.71% ▼ 1.23% Sep 30, 2026
6 Xtrackers MSCI World Swap ETF 1C 393.42K 0.60% ▼ 0.63% Dec 31, 2025
7 Vanguard Russell 2000 ETF 344.92K 0.52% ▲ 1.01% Sep 30, 2026
8 Fidelity Extended Market Index 332.15K 0.50% ▲ 1.12% Aug 31, 2026
9 Schwab US Small-Cap ETF™ 306.39K 0.46% ▲ 0.07% Sep 30, 2026
10 iShares US Pharmaceuticals ETF 214.15K 0.32% ▲ 0.31% Sep 30, 2026

Financial Highlights

▼
Market Cap: $504.30M
EBITDA: $-12.77M
Book Value: $-0.47
Earnings/Share: $-0.53
Profit Margin: -10.85%
Operating Margin: -5.17%
ROA (TTM): -5.68%
ROE (TTM): -18,729.61%
Revenue (TTM): $316.49M
Revenue/Share (TTM): $4.86
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 21.20%

Valuation Metrics

Enterprise Value: $606.43M
Trailing P/E: 0.00
Forward P/E: 15.67

Shares Statistics

Shares Outstanding: 66.05M
Shares Float: 49.77M
% Insiders: 11.25%
% Institutions: 77.67%
Shares Short: 6.41M
Shares Short (Prior Month): 5.63M
Short Ratio: 8.44
Short % Float: 9.82%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$297.18M
Cost of Goods Sold
adjust
$-104.41M
Gross Profit
subtotal
$192.76M
SG&A
adjust
$-220.79M
R&D
adjust
$-9.58M
Operating Income
subtotal
$-37.60M
Other / Non-Operating Items
adjust
$-14.04M
Net Income
subtotal
$-51.64M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about EOLS.US!